Ryan Black, MD
Urology · Huntsville, ALNPI 1427492354
Payments from drug & device makers
Across 257 payments — averaging $26.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$1K
- Boston Scientific$1K
- Sumitomo Pharma America, Inc.$711
- Astellas Pharma US Inc$634
- Endo Pharmaceuticals Inc.$610
- Medtronic$381
- plus $2K from 32 others
What the payments were for
- Travel & lodging$1,52122%
- Food & beverage$4,94472%
- Education$3435%
- Entertainment$421%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 30 | $1,480 |
| Boston Scientific | 22 | $1,222 |
| Sumitomo Pharma America, Inc. | 45 | $711 |
| Astellas Pharma US Inc | 33 | $634 |
| Endo Pharmaceuticals Inc. | 24 | $610 |
| Medtronic(2 entities) | 11 | $381 |
| AbbVie(2 entities) | 20 | $288 |
| Myriad Genetic Laboratories, Inc. | 3 | $219 |
| Pfizer | 9 | $181 |
| Urovant Sciences Inc | 7 | $127 |
| Procept Biorobotics Corporation | 3 | $116 |
| Endo USA, Inc. | 5 | $107 |
| Urogen Pharma, Inc. | 4 | $88 |
| Olympus America Inc. | 3 | $71 |
| Antares Pharma, Inc. | 3 | $55 |
| Clarus Therapeutics Inc. | 3 | $46 |
| Rochester Medical Corporation | 3 | $43 |
| EDAP Technomed Inc | 1 | $42 |
| Tolmar, Inc. | 2 | $41 |
| Axonics, Inc. | 2 | $33 |
| Zyla Life Sciences, Inc. | 2 | $26 |
| Innovation Technologies Inc | 1 | $25 |
| Civco Medical Instruments | 1 | $25 |
| Blue Earth Diagnostics | 1 | $25 |
| 180 Medical, Inc. | 1 | $24 |
| Hollister Incorporated | 1 | $23 |
| Agiliti Surgical, Inc. | 1 | $22 |
| Travere Therapeutics, Inc. | 6 | $21 |
| Halozyme Inc | 1 | $20 |
| Tolmar Pharmaceuticals, Inc. | 1 | $18 |
| Kerecis Limited | 1 | $18 |
| Immunitybio, Inc. | 1 | $17 |
| Accord Healthcare, Inc. | 1 | $17 |
| Bayer | 1 | $16 |
| Calyxo, Inc. | 1 | $15 |
| Ambu Inc. | 1 | $14 |
| Profound Medical Corp. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TITAN$853
- GENERAL KIDNEY STONE DISEASE$758
- XIAFLEX$250
- INTERSTIM$178
- BRACAnalysis CDx$108
How this compares
$6,849 in reported general payments places this provider in the 65th percentile of 179 urology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 278 | $150,896 |
| GemtesaVibegron | 83 | $66,683 |
| Tolterodine Tartrate ErTolterodine Tartrate | 138 | $11,570 |
| Mirabegron ErMirabegron | 13 | $7,716 |
| Tamsulosin Hcl | 465 | $6,984 |
| Finasteride | 193 | $2,945 |
| Estradiol | 28 | $2,376 |
| Solifenacin Succinate | 40 | $2,130 |
| Testosterone | 14 | $2,037 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 72 | $1,713 |
| Silodosin | 38 | $1,609 |
| Potassium Citrate ErPotassium Citrate | 15 | $1,546 |
| Testosterone Cypionate | 18 | $1,006 |
| Cephalexin | 86 | $965 |
| Oxybutynin Chloride ErOxybutynin Chloride | 44 | $916 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $634 | $150,896278 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $711 | $66,68383 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 179 urology providers in Alabama.
Other urology in Huntsville
- James McMurrayHuntsville$4.7M
- Jacob BrittHuntsville$14K
- Victor JiminezHuntsville$9K
- James FlattHuntsville$9K
- Joseph PettusHuntsville$7K
- Vincent BivinsHomewood$1.3M
- Charles WhiteMobile$735K
- Thomas ChiBirmingham$628K
- Charles BuggHomewood$544K
- Charles PeytonBirmingham$543K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.